PHASE II TRIAL OF RITUXIMAB PLUS CHLORAMBUCIL FOLLOWED BY A 2‐YEAR SUBCUTANEOUS RITUXIMAB MAINTENANCE IN MALT LYMPHOMA PATIENTS (IELSG38). (17th June 2021)

• Record Type: Journal Article
• Authors: Pirosa, M. C.; Orsucci, L.; Feugier, P.; Tani, M.; Ghesquieres, Hervé; Musuraca, G.; Baldini, L.; Merli, F.; De Renzis, B.; Gyan, E.; Gini, G.; Marino, D.; Gressin, R.; Morschhauser, F.; Palombi, F.; Cavallo, F.; Conconi, A.; Le Gouill, S.; Tilly, Hervé; Zanni, M.; Cabras, M. G.; Capochiani, E.; Califano, C.; Molinari, A. L.; Pulsoni, A.; Angrilli, F.; Cartron, G.; Casasnovas, O.; Devizzi, L.; Haioun, C.; Houot, R.; Liberati, A. M.; Occhini, U.; Merli, M.; Pietrantuono, G.; Re, F.; Spina, M.; Esposito, F.; Bertoni, F.; Rossi, D.; Ielmini, N.; Luminari, S.; Cavalli, F.; Zucca, E.; Stathis, A.; Thieblemont, C.;
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Chemotherapy Combination -- Therapies Immunotherapy; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.79_2879
• Languages: English
• ISSNs: 0278-0232